Please assess the completion status of the following clinical trial:

Trial Title: CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 to 80 years of age, inclusive;~2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement ≥10%, as judged by the Investigator;~3. PASI score ≥12 (Appendix 3)~4. Static PGA ≥3 (Appendix 2)~5. Candidate for systemic treatment or phototherapy for psoriasis;~6. Duration of psoriasis of at least 6 months;~7. Elevated whole blood A3AR expression level, defined as ≥ 1.5-fold over a predetermined normal population standard at Screening;~8. Females of child-bearing potential must have a negative serum pregnancy test at screening;~9. Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study;~10. Ability to complete the study in compliance with the protocol; and~11. Ability to understand and provide written informed consent.~Exclusion Criteria:~1. Psoriasis limited to erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis in the absence of plaque psoriasis;~2. Prior treatment with apremilast within 4 weeks prior to the Baseline visit, or contraindication to apremilast;~3. Treatment with systemic retinoids, corticosteroids, tofacitinib, or immunosuppressive agents (e.g., methotrexate, cyclosporine) within 4 weeks of the Baseline visit;~4. Treatment with a biological agent (etanercept, adalimumab, efalizumab, infliximab, ustekinumab, alefacept, secukinumab, or others, including investigational agents) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit;~5. Treatment with high potency topical dermatological corticosteroids (Class I-III in US, Class III-IV in Europe), Vitamin D analogs, keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit;~6. Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period;~7. Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period, unless dose has been stable for 3 months prior to the Screening visit and will remain stable throughout the trial;~8. Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal at Screening;~9. Liver aminotransferase levels greater than 1.5 times the laboratory's upper limit of normal at Screening;~10. Electrocardiogram (ECG) at Screening shows abnormalities which, in the judgment of the Investigator, are clinically significant and could, in the judgment of the Principal Investigator, compromise subject safety;~11. Active gastrointestinal disease which could interfere with the absorption of oral medication;~12. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the Investigator;~13. Active drug or alcohol dependence;~14. History of depression or suicidal ideation within the past year;~15. Concomitant use of strong cytochrome P450 inducers, eg, rifampin, phenobarbital, phenytoin, carbamazepine;~16. Previous participation in a CF101 clinical trial;~17. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;~18. Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to the Screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CF101 2mg (Type: EXPERIMENTAL): CF101 2mg, orally q12 hours
- CF101 3mg (Type: EXPERIMENTAL): CF101 3mg, orally q12 hours
- Apremilast 30mg (Type: ACTIVE_COMPARATOR): Apremilast 30mg, orally q12 hours
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control , orally q12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).